Literature DB >> 9826579

CD30: expression and function in health and disease.

R Horie1, T Watanabe.   

Abstract

CD30 was originally described as a marker of Hodgkin's and Reed-Sternberg cells in Hodgkin's lymphoma. Cloning and characterization of cDNAs encoding CD30 and its ligand (CD30L) established these proteins as members of the tumor necrosis factor receptor (TNFR) and tumor necrosis factor (TNF) superfamilies, respectively. Expression of CD30 is mostly restricted to virus-infected lymphocytes, neoplasms of lymphoid origin and a subset of activated T cells which produce Th2-type cytokines. The ligand is present on activated T cells, resting B cells, granulocytes, and the medulla of the thymus (epithelial cells and Hassal's corpuscles) as well as in various leukemia cells. The biological function of CD30 is pleiotropic but has come to be understood in the context of co-stimulatory signals. Signal transduction of CD30 utilizes signal transducers, TNFR-associated factors (TRAF1, 2, 3 and 5), which are shared by other TNFR family members. Mechanisms of signal transduction leading to diverse biological functions remain to be elucidated. Copyright 1998 Academic Press

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9826579     DOI: 10.1006/smim.1998.0156

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  77 in total

1.  Thymocyte apoptosis.

Authors:  Y Yang; J D Ashwell
Journal:  J Clin Immunol       Date:  1999-11       Impact factor: 8.317

Review 2.  Monoclonal antibodies.

Authors:  P N Nelson; G M Reynolds; E E Waldron; E Ward; K Giannopoulos; P G Murray
Journal:  Mol Pathol       Date:  2000-06

3.  CD4+CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30-dependent mechanism.

Authors:  Zhenhua Dai; Qi Li; Yinong Wang; Ge Gao; Lonnette S Diggs; George Tellides; Fadi G Lakkis
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

4.  Marek's disease is a natural model for lymphomas overexpressing Hodgkin's disease antigen (CD30).

Authors:  S C Burgess; J R Young; B J G Baaten; L Hunt; L N J Ross; M S Parcells; P M Kumar; C A Tregaskes; L F Lee; T F Davison
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-08       Impact factor: 11.205

5.  Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation.

Authors:  Deborah L Regidor; Roger Detels; Elizabeth C Breen; Daniel P Widney; Lisa P Jacobson; Frank Palella; Charles R Rinaldo; Jay H Bream; Otoniel Martínez-Maza
Journal:  AIDS       Date:  2011-01-28       Impact factor: 4.177

6.  Frequent expression of the variant CD30 in human malignant myeloid and lymphoid neoplasms.

Authors:  R Horie; V Gattei; K Ito; S Imajo-Ohmi; T Tange; J Miyauchi; A Pinto; M Degan; A De Iuliis; F Tassan Mazzocco; F M Rossi; M Higashihara; T Watanabe
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 7.  Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.

Authors:  Andrew M Rogers; Jonathan E Brammer
Journal:  Curr Hematol Malig Rep       Date:  2020-08       Impact factor: 3.952

8.  Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy.

Authors:  Satoshi Nagata; Tomoko Ise; Masanori Onda; Kazuyasu Nakamura; Mitchell Ho; Andrew Raubitschek; Ira H Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-19       Impact factor: 11.205

9.  Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease.

Authors:  Robert Zeiser; Vu H Nguyen; Jing-Zhou Hou; Andreas Beilhack; Elizabeth Zambricki; Martin Buess; Christopher H Contag; Robert S Negrin
Journal:  Blood       Date:  2006-10-26       Impact factor: 22.113

Review 10.  Immunotherapies for Hodgkin's lymphoma.

Authors:  Yvette L Kasamon; Richard F Ambinder
Journal:  Crit Rev Oncol Hematol       Date:  2007-11-19       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.